Indaptus Therapeutics (INDP) Cash & Equivalents (2020 - 2026)

Indaptus Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 61.51% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 61.51% YoY), while the FY2025 annual figure was $8.5 million, up 47.02% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.5 million, down from $8.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $33.2 million in Q1 2022, with the low at $1.5 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $7.4 million (2024), against an average of $9.9 million.
• Peak annual rise in Cash & Equivalents reached 227.74% in 2022, while the deepest fall reached 83.95% in 2022.
• Indaptus Therapeutics' Cash & Equivalents stood at $9.6 million in 2022, then soared by 38.8% to $13.4 million in 2023, then sank by 56.69% to $5.8 million in 2024, then surged by 47.02% to $8.5 million in 2025, then slumped by 82.4% to $1.5 million in 2026.
• Business Quant data shows INDP's Cash & Equivalents at $1.5 million in Q1 2026, $8.5 million in Q4 2025, and $5.8 million in Q3 2025.